



Oncology Office Hematology Requisition

Client Information		Patient Information		
Required Information		Last Name:	□ Male □ Female	
Account #:	Account Name:	First Name:M.I	Medical Record #:	
Street Address:		Date of Birth: mm / dd / yyyy	Other Pt ID/Acct #:	
-		Client represents it has obtained informed consent from	patient to perform the services described herein.	
Phone: Fax:		Specimen Information		
Additional Reporting Fax:		☐ Mobile Phlebotomy Request NeoGenomics will reach out to patient to schedule ar	pointment - Patient Phone:	
Requisition Completed by:	Date:	Specimen ID:	Block ID:	
Ordering Physician:(please print: Last, First):	NPI #:	Fixative/Preservative:	Block ID: AM	
Treating Oncologist/Physician:	NPI #:	Retrieved Date: mm / dd / yyyy		
(please print: Last, First): The undersigned certifies that he/she is li	icensed to order the test(s) listed below and that such test(s) are medi-	Hospital Discharge Date: mm/ dd	/ yyyy	
cally necessary for the care/treatment of	•	Body Site:	arv.	
Authorized Signature:	Date:	-	☐ Bone Marrow [must provide CBC Report]:	
Billing Information		Green Top(s) Purple Top(s) Core Biopsy Clot		
Required: Please include face sheet and front/back of patient's insurance card.		☐ Peripheral Blood: Green Top(s) Purple Top(s) Other ☐ Smears: Air Dried Fixed Stained (type of stain)		
Patient Status (Must Choose 1):	Bill to:	☐ Smears: Air Dried Fixed	Stained (type of stain)	
☐ Non-Hospital Patient	☐ Insurance ☐ Patient/Self-Pay ☐ Medicare ☐ Medicaid ☐ Client Bill	☐ Paraffin Block(s) #:		
☐ Hospital Patient (in) ☐ Hospital Patient (out)	☐ OP Molecular to MCR, all other testing to Client☐ Bill charges to other Hospital/Facility:	□ Choose best block (for global molecular/NG: Submit ≤4 blocks. Blocks will be combined for money.	S testing only)	
See back for definitions.	——————————————————————————————————————		or each if sending multiple blocks. See back for details.	
Prior Authorization #	See neogenomics.com/billing for more info.	Specimen Retrieval		
Clinical Information Client Services will request specimen from			ology site.	
Required: Please attach patient's pathology report (required), clinical history, and other applicable report(s).		Pathology Site:		
ICD 10 (Diagnosis) Code/Narrative (Required):		Address:Fax		
Reason for Referral:		11101161 a	•	
☐ New Diagnosis ☐ Relapse/Refra		Required Items ☐ Patient Demographics	☐ Pathology Report	
Bone Marrow Transplant	El Allegaria	☐ Copy of Insurance Card	☐ Clinical History	
□ None □ Autologous	☐ Allogeneic ☐ Sex Mismatch	☐ CBC Within Last 30 Days	☐ Relevant Treatment History	
☐ Blood and/or Bone Marrow ☐ Paraffin block for Morphology: Lymphoma Consult ☐ Lymph Node/Tissue for Lympho *Split fresh specimens to RPMI and ☐ Paraffin block for Morphology	to follow the materials submitted. ma* Please attach CBC for Blood and I formalin Do not add NGS Profile with	` ' '	1	
Morphology		Molecular Genetics	☐ JAK2 Exon 12-13* (non-V617F)	
☐ Blood and/or Bone Marrow		☐ ABL1 Kinase Domain (Gleevec® resistance) ☐ B-Cell Gene Rearrangement	☐ JAK2 V617F - Qualitative ☐ If negative, reflex to JAK2 Exon 12-13 (non-V617F)	
NeoTYPE® and Neo Comprehensive® Cancer Profiles		☐ BCR-ABL1 Standard p210, p190	□ If negative, reflex to CALR	
	a Profile ☐ Neo Comprehensive – Heme Cancers	☐ BCR-ABL1 Standard p210, p190 with reflex to ABL1 Kinase Domain if positive	□ If negative, reflex to MPL □ JAK2 V617F - Quantitative	
☐ ALL Profile ☐ Neo Comprehensive – Myeloid Disorders		BCR-ABL1 Standard p210, p190 with reflex to BCR-ABL1 Non-Standard p230 if negative	KIT (c-KIT)	
☐ AML Prognostic Profile ☐ Follicular Lymphoma Profile (FFPE only)		☐ BCR-ABL1 Non-Standard p230	 ☐ MPL Mutation Analysis ☐ MPN JAK2 V617F with Sequential Reflex 	
CLL Profile	☐ Lymphoid Disorders Profile☐ Lymphoma Profile	☐ BRAF ☐ BTK Inhibitor Acquired Resistance Panel	to JAK2 Exon 12-13, CALR, & MPL MYD88 Mutation Analysis	
☐ Add IgVH Mutation Analysis	☐ MDS/CMML Profile	☐ Calreticulin (CALR) Mutation Analysis	☐ NPM1 MRD Analysis	
F. 0 ()		☐ CEBPA Mutation Analysis☐ CXCR4 Mutation Analysis	☐ NPM1 Mutation Analysis ☐ PML- RARA, t(15;17)	
Flow Cytometry		☐ FLT3 Mutation Analysis	☐ Rapid AML Therapeutic Panel	
Please attach CBC with all flow requests on blood (required).		☐ IDH1/IDH2 by PCR ☐ IgH Clonality by NGS	☐ RUNX1-RUNX1T1 (AML1-ETO), t(8;21) ☐ T-Cell Receptor Gamma	
Diagnostic/Prognostic Panels	MRD Panels AML MRD Panel	Baseline testing of original primary sample required IgVH Mutation Analysis	☐ T-Cell Receptor Beta	
☐ Standard L/L Panel (24 Markers ☐ Extended L/L Panel (31 Markers	D D ALL MDD (D M)	inv(16) CBFB-MYH11	☐ TP53 Mutation Analysis ☐ Other	
☐ High Sensitivity PNH	☐ B-ALL MRD (Peripheral Blood)	HemeFISH®		
. 5 - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2	CLL MRD	☐ Anaplastic Large Cell Lymphoma (ALCL)	☐ High-Grade B-Cell Lymphoma Reflex	
	☐ Myeloma (MM) MRD	☐ ALL - Adult ☐ ALL - Pediatric	□ Low-Grade/Small B-Cell Lymphoma□ MDS Extended	
Cytogenetics		☐ ALL, Ph-Like ☐ AML Standard	☐ MDS Standard ☐ Reflex to ETV6 (12p13), MLL (11q23)	
Oncology Chromosome Analysis		☐ Reflex to 5q-/-5, 7q/-7, DEK/NUP214 t(6;9), p53	and +19 if negative	
☐ Reflex to FISH if cytogenetics is normal (reflex FISH panel must be selected) ☐ Reflex to FISH if cytogenetics is incomplete (<20 metaphases)		(17p13.1)/NF1 (17q11) and NUP98 (11p15) if negation AML Non-Favorable Risk	ative MPN NHL	
☐ MDS Standard FISH		BCR/ABL1/ASS1 t(9;22)	☐ Plasma Cell Myeloma	
☐ MDS Extended FISH		☐ Eosinophilia	□ Do not reflex to IgH Complex□ Plasma Cell Myeloma IgH Complex	
☐ Follow-up Constitutional Chromosome Analysis		☐ High-Grade/Large B-cell Lymphoma☐ Reflex to BCL6/MYC, IGK/MYC, IGL/MYC if MYC	☐ Plasma Cell Myeloma Prognostic Panel	
(only if recommended by Oncology Chromosome Analysis)		and IGH/MYC-	Other	
☐ Other		 Plasma Cell Enrichment will be performed on all bone ma 	rrow samples having plasma cell FISH tests.	

Specimen Requirements

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call the Client Services team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Additional Specimen Information

If submitting multiple blocks, clients must indicate either "Choose best block (global molecular/NGS testing only)", or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call the Client Services team with any questions regarding specimen information.

Definitions of Patient Status for Specimen Origin

Non-Hospital Patient: Patient is not registered at a hospital (neither an in-patient nor out-patient)

Hospital Patient (in): Patient is registered and admitted to a hospital overnight

Hospital Patient (out): Patient is registered and admitted to a hospital, then discharged before the end of the day

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com/test-menu.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

FISH

Plasma cell myeloma FISH panels: Plasma cell enrichment will be performed on bone marrow samples having plasma cell FISH. Sample should be received at NeoGenomics Laboratories within 72 hours of collection.